MDMB-FUBICA

MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.

MDMB-FUBICA
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC23H25FN2O3
Molar mass396.462 g·mol−1
3D model (JSmol)

It was first detected by the EMCDDA in Sweden in February 2015.[1] It is often sold in e-liquid form for use in an electronic cigarette.[2]

Side effects

MDMB-FUBICA's indazole analogue MDMB-FUBINACA has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015.[3]

Legality

MDMB-FUBICA is banned in Sweden.[4]

See also

References

  1. "Hamarosan: 2015. Évi Európai Kábítószer - Jelentés" (PDF). Hungarian National Focal Point (NFP). June 2015. Retrieved 23 July 2015.
  2. Peace MR, Krakowiak RI, Wolf CE, Poklis A, Poklis JL (February 2017). "Identification of MDMB-FUBINACA in commercially available e-liquid formulations sold for use in electronic cigarettes". Forensic Science International. 271: 92–97. doi:10.1016/j.forsciint.2016.12.031. PMC 5511053. PMID 28076838.
  3. "Очередная жертва спайса". Federal Drug Control Service of the Russian Federation. 17 March 2015. Archived from the original on 14 July 2015. Retrieved 24 July 2015.
  4. "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. 1 June 2015. Retrieved 24 July 2015.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.